18561331. METHODS OF TREATMENT OF CANCER PATIENTS HAVING ALTERED SETD2 BIOMARKER WITH A PD-1 ANTAGONIST simplified abstract (Merck Sharp & Dohme LLC)

METHODS OF TREATMENT OF CANCER PATIENTS HAVING ALTERED SETD2 BIOMARKER WITH A PD-1 ANTAGONIST

Organization Name

Merck Sharp & Dohme LLC

Inventor(s)

Razvan Cristescu of Newton MA (US)

Elisha Dettman of Landsdale PA (US)

Yongjin Li of Newton MA (US)

Karla Gabriela Rodriguez-lopez of Westfield NJ (US)

Michael Nebozhyn of Colmar PA (US)

Rodolfo Fleury Perini of Wynnewood PA (US)

Raluca Andreia Predoiu of Penn Valley PA (US)

Yiwei Zhang of Katy TX (US)

METHODS OF TREATMENT OF CANCER PATIENTS HAVING ALTERED SETD2 BIOMARKER WITH A PD-1 ANTAGONIST - A simplified explanation of the abstract

This abstract first appeared for US patent application 18561331 titled 'METHODS OF TREATMENT OF CANCER PATIENTS HAVING ALTERED SETD2 BIOMARKER WITH A PD-1 ANTAGONIST

The present disclosure discusses methods of treating cancer in patients with altered SETD2 biomarker activity using a treatment regimen involving a PD-1 receptor antagonist.

• This patent application focuses on treating cancer in patients with specific biomarker alterations.
• The treatment regimen includes an antagonist of the PD-1 receptor.
• The innovation targets patients with SETD2 biomarker activity changes.
• The methods aim to improve cancer treatment outcomes in this patient population.
• The application highlights the potential of PD-1 receptor antagonists in personalized cancer therapy.

Potential Applications: - Personalized cancer treatment based on biomarker activity. - Targeted therapy for patients with specific genetic alterations. - Advancements in precision medicine for cancer care.

Problems Solved: - Addressing the challenge of treating cancer in patients with altered biomarker activity. - Improving treatment efficacy in a subset of cancer patients with SETD2 biomarker changes.

Benefits: - Enhanced treatment outcomes for patients with specific biomarker alterations. - Tailored therapy based on individual genetic profiles. - Potential for improved survival rates and quality of life for cancer patients.

Commercial Applications: Title: Personalized Cancer Therapy with PD-1 Receptor Antagonists This technology has commercial applications in pharmaceutical companies developing targeted cancer therapies. It can also benefit healthcare providers offering personalized treatment options for cancer patients.

Questions about the technology: 1. How does the use of PD-1 receptor antagonists impact cancer treatment outcomes in patients with altered SETD2 biomarker activity? 2. What are the potential challenges in implementing personalized cancer therapy based on biomarker alterations?

Original Abstract Submitted

The present disclosure describes methods of treatment of cancer in patients with altered activity or amount of a SETD2 biomarker with a treatment regimen comprising an antagonist of Programmed Death 1 receptor (PD-1).